Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Conestat alfa may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Ruconest contains conestat alfa as the active substance. Conestat alfa is a recombinant (not blood-derived) form of human C1 inhibitor (rhC1-INH). Ruconest is to be used by adults, adolescents, and children (aged 2 years and above) with a rare inherited blood disorder, called Hereditary Angioedema (HAE). These patients have a shortage of the C1 inhibitor protein in their blood. This can lead to repeated attacks of swelling, pain in the abdomen, difficulty breathing and other symptoms. The administration of Ruconest is to resolve the shortage of C1 inhibitor and will lead to reduction of symptoms of an acute attack of HAE.
2.
e Ruconest
Do not use Ruconest • If you are or think you are allergic to rabbits. • If you are allergic to conestat alfa or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Talk to your doctor before using Ruconest. If you experience allergic reactions e.g. hives, rash, itching, dizziness, wheezing, difficulty breathing or your tongue swells up following the administration of Ruconest, you should seek emergency medical assistance so that symptoms of your allergic reaction can be treated urgently. Before you start treatment with Ruconest, it is important that you tell your doctor if you have, or have had, problems with your blood clotting (thrombotic events). You will be carefully monitored if this is the case. Hypersensitivity reactions cannot be excluded and may have symptoms similar to angioedema attacks.
2
Children and adolescents Do not give this medicine to children under 2 years old. Ruconest has not been studied in children younger than 5 years of age. Your doctor will determine whether treatment of your child with Ruconest is appropriate. Additional monitoring of your child for symptoms of allergic reactions during and after administration is needed. Other medicines and Ruconest Tell your doctor if you are taking, have recently taken or might take any other medicines. If you are receiving tissue type plasminogen activator as acute treatment for blood clots, you should not be treated with Ruconest at the same time. Pregnancy and breast-feeding It is not recommended to use Ruconest during pregnancy or breast-feeding. If you plan becoming pregnant, discuss with your doctor before starting to use Ruconest. Driving and using machines Do not drive or use machinery if you feel dizzy or suffer from headache after using Ruconest. Ruconest contains sodium (19.5 mg per vial) This should be taken into consideration by patients on a controlled sodium diet.
3.
Ruconest
Ruconest will be initiated by a doctor who is specialised in the diagnosis and treatment of hereditary angioedema. Ruconest must be administered by a healthcare professional until you or your caregiver are properly trained and capable to administer Ruconest. Always use this medicine exactly as described in this leaflet or as your doctor or nurse have told you. Check with your doctor or nurse if you are not sure. Ruconest is administered into a vein over about 5 minutes. Your dose will be worked out based on your body weight. Most of the time a single dose is sufficient. An additional dose could be administered if your symptoms do not improve after 120 minutes (for adults and adolescents) or 60 minutes (for children). No more than 2 doses, calculated according to step 7, should be given within 24 hours. You or your caregiver may inject Ruconest only after receiving adequate instructions and training from your doctor or nurse. Instructions for use Do not mix or administer Ruconest with other medicines or solutions. The following describes how Ruconest solution must be prepared and administered. Before you begin • Ensure the kit package is complete and contains all components listed in section 6 of this leaflet. • In addition to the kit, the following is required:
•
the outer carton reflects the date of the component with the shortest shelf-life. Allow the number of powder and solvent vials required according to step 1, to reach room temperature.
Preparation of solution Step 1: Cleaning and other requirements • Wash your hands carefully. • Put the powder and solvent vials required on a flat and clean surface.
•
After disinfection, do not touch the stoppers with your fingers or anything else.
Step 3: Mounting of adapters on vials • Take a packaged adapter in one hand and remove the lid. The adapter must remain in its plastic packaging. • Put the adapter onto a powder vial, piercing the stopper, until it snaps onto the vial neck.
4
• • •
Leave the packaging on the adapter until you attach the syringe in steps 4 and 5. Repeat the above steps for mounting an adapter on the solvent vial. All adapters supplied with the kit are identical. If you need to use a second powder and solvent vial, repeat the above steps.
Step 4: Drawing up solvent • Take a sterile syringe out of its packaging. • Remove the packaging from the adapter on the solvent vial.
•
Hold the adapter with one hand. With the other hand, attach the syringe and secure by turning it clockwise until it stops.
•
Turn the whole – solvent vial with adapter and syringe – upside down. While keeping it vertical, slowly draw in 14 ml solvent. If air bubbles appear, minimise as far as possible by gently tapping the syringe and applying gentle pressure by pushing the plunger into the syringe. Continue to fill the syringe with 14 ml solvent.
•
Unlock the syringe from the adapter by turning counter-clockwise.
5
• •
Leave the remainder of the solvent in the vial and discard the vial. Place the syringe on the work surface, taking care not to touch the surface or any other object with the syringe tip.
Step 5: Adding solvent to powder and dissolving • Remove the packaging from the adapter on the powder vial. • Take the syringe with solvent that you prepared in step 4. • Hold the adapter with the other hand and attach the syringe. Secure the syringe by turning it clockwise until it stops. • Push the solvent slowly, in a single motion, into the powder vial in order to minimise foaming.
•
Leave the syringe on the adapter and gently swirl the vial for approximately half a minute. Do not shake. After swirling, leave the vial on the surface for several minutes until the solution has become clear. If undissolved powder is still present, repeat the procedure.
•
Repeat steps 4 and 5 if you need to prepare a second solution.
Step 6: Check prepared solutions • Check whether the powder in the vial(s) has dissolved completely and the plunger is completely pushed down in the syringe. • After the powder has dissolved, the solution should be clear and colourless. • Do not use the prepared solution if it is cloudy, contains particles or has changed colour. Inform your 6
healthcare professional if this occurs. Small amounts of foam are acceptable.
Step 7: Drawing up prepared solution • Calculate the millilitres of prepared solution to be injected. Body weight Millilitres of prepared solution to be injected below 84 kg Body weight in kg divided by three 84 kg and above 28 ml •
Draw in the volume of prepared solution, while keeping the syringe in the vertical position. If you have prepared:
• • •
Never exceed the volume of 14 ml per syringe. Unlock the syringe(s) by turning it counter-clockwise and discard the vial(s) with adapter. Place the syringe(s) on the work surface, taking care not to touch the surface or any other object with the syringe tip.
Step 8: Check prepared syringes • Recheck that the volume in the syringe(s) you prepared in step 7 is correct. Administration into a vein It is very important that the prepared solution is injected directly into a vein and not into an artery or the surrounding tissue. Inject the Ruconest solution immediately after preparation, preferably while seated. Step 9: Required components • Check that all required components are on the work surface:
–
1 alcohol pad 1 sterile non-woven pad 1 self-adhesive plaster 1 tourniquet 1 plaster for securing the needle
Step 10: Preparation of the infusion set • Remove the screw cap from the end of the infusion set. This is the end which has no needle. • Hold this end with one hand, attach the syringe tip end and secure by turning clockwise until it stops. • Hold the syringe with the tip pointing upwards. Gently press the syringe plunger to carefully fill the infusion set with the prepared solution.
•
Check that no air is present in the syringe, infusion tube or the needle.
Step 11: Preparing the injection site • Position the tourniquet above the injection site – preferably the middle part of the upper arm. Tighten it to compress the vein. This should be boosted by tightening your fist. • Feel, with your other hand, for an appropriate vein. • Disinfect the injection site thoroughly with an alcohol pad and let the skin dry.
Step 12: Administration of the prepared solution • Remove the needle cap. • Carefully insert the needle of the infusion set, at the flattest possible angle, into the vein.
• • • •
Secure the needle by applying the plaster, around 7 cm long, over the wings of the needle. Carefully pull back the syringe plunger slightly until you see blood being drawn into the tubing, to ensure that the needle is in the vein. Release the tourniquet. If there is no blood in the tubing, remove the needle, repeat all steps from beginning of step 11 and 8
•
•
reposition the needle. If blood is present, gently inject the solution into the vein, as shown in the picture. Inject over about 5 minutes.
If you have prepared two syringes:
• • •
Next, put the self-adhesive plaster on the injection site. Fold down the yellow protection cap over the needle. Safely dispose of the used infusion set with needle, any unused solution, the syringe and the empty vial in an appropriate medical waste container as these materials may hurt others if not disposed of properly. Do not reuse equipment.
Step 14: Documenting the administration Please record (e.g. in your diary): • date and time of the administration • the batch number written on the label of the powder vial If you use more Ruconest than you should Contact your doctor or nearest hospital if this occurs. If you have any further questions on the use of this medicine, ask your doctor. 9
4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If your symptoms get worse and/or you develop a rash, tingling, difficulty breathing or your face or tongue swells up, get medical attention immediately. This may indicate that you have developed an allergy to Ruconest. Some side effects may occur during treatment with Ruconest: Common: may affect up to 1 in 10 people • Nausea Uncommon: may affect up to 1 in 100 people • Abdominal pain, diarrhoea • Sensation of tingling, prickling or numbness in the mouth • Headache, dizziness • Reduced sense of touch or sensation in skin or limbs • Throat irritation • Hives • Swelling of the ears or the area around the ears • Allergic shock Not known: the frequency is not known
5.
Ruconest
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and on the label of the vial after EXP. The expiry date refers to the last day of that month. Do not store above 25°C. Keep the powder vial in the vial carton in order to protect from light. Before Ruconest can be administered, the powder needs to be dissolved in the solvent included in the package (see section 3). Once reconstituted, the product should be used immediately. Do not use this medicine if, after dissolving, you notice particles in the solution or if the solution is discoloured. Small amounts of foam are acceptable. 10
6.
What Ruconest contains Powder vial: • The active substance is conestat alfa. Each powder vial contains 2100 units of conestat alfa, corresponding to 2100 units per 14 ml after reconstitution, or a concentration of 150 units/ml. • The other ingredients of the powder are sucrose, sodium citrate (E331) and citric acid. Solvent vial: • The ingredient of the solvent is water for injections. What Ruconest looks like and contents of the pack Ruconest is presented as a single glass vial containing a white to off-white powder for solution for injection together with one glass vial containg a clear, colourless solvent to dissolve the powder. After dissolving the powder in water for injections, the solution is clear and colourless. Ruconest is supplied with an administration kit in a carton box containing:
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Pharming Group N.V. Darwinweg 24 2333 CR Leiden The Netherlands Manufacturer: Pharming Technologies B.V. Darwinweg 24 2333 CR Leiden The Netherlands
This leaflet was last revised in July 2023.
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
11
The following information is intended for healthcare professionals only: POSOLOGY AND METHOD OF ADMINISTRATION Posology Body weight up to 84 kg
=
body weight (kg) times 50 (U/kg) 150 (U/ml)
=
body weight (kg) 3
Body weight of 84 kg or greater
SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING Preparation and handling Each vial of Ruconest is for single use only. Ruconest is intended for intravenous administration after reconstitution with water for injections. An aseptic technique should be used for reconstitution, combining and mixing the solutions. Reconstitution 1. Each vial of Ruconest (2100 U) should be reconstituted with 14 ml water for injections. 2. Disinfect the rubber stoppers of the powder and solvent vials and put a vial adapter onto each solvent and powder vial until it snaps onto the vial neck. 3. Attach a syringe to the adapter on a solvent vial and turn clockwise until it locks. Draw in 14 ml of solvent. Unlock the syringe from the adapter by turning counter clockwise. Repeat this step if two powder vials need to be reconstituted. 4. Attach a syringe with solvent to the adapter on a powder vial and turn clockwise until it locks. Water for injections should be added slowly to avoid forceful impact on the powder and mixed gently to minimise foaming of the solution. Leave the syringe on the adapter. Repeat this step if a second powder vial needs to be reconstituted. 5. The reconstituted solution in each vial contains 150 U/ml and appears as a clear colourless solution. 12
The reconstituted solution in each vial should be inspected for particulate matter and discoloration. A solution exhibiting particulates or discoloration should not be used. Small amounts of foam are acceptable. The medicinal product should be used immediately. Administration 1. Draw in the required volume of prepared solution. Never exceed 14 ml per syringe. Unlock the syringe(s) by turning counter clockwise and discard vial(s) with adapter 2. Attach the infusion set to the syringe and turn clockwise until it locks. Hold the syringe with the tip pointing upwards and gently press the plunger to fill the infusion set with the solution 3. Disinfect the injection site with an alcohol pad. Remove the needle cap from the needle of the infusion set and carefully insert the needle into the vein. 4. Ensure that the tourniquet is released. Gently inject the solution into the vein – inject over about 5 minutes. 5. If two syringes were prepared: fold over the tubing to prevent backflow, unscrew the empty syringe from the infusion set (counter clockwise) and immediately replace it with the second syringe. Gently inject the solution of the second syringe. Disposal Please safely dispose of the used infusion set with needle, any unused solution, the syringe and the empty vial in an appropriate medical waste container as these materials may hurt others if not disposed of properly. Do not reuse equipment.
13
Ruconest 2100 U powder and solvent for solution for injection comes as injection. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Ruconest 2100 U powder and solvent for solution for injection is conestat alfa.
Medicines with the same active substance, strength and form include: Ruconest 2100 U powder for solution for injection. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Ruconest 2100 U powder and solvent for solution for injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Ruconest is indicated for treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency.
Ruconest should be initiated under the guidance and supervision of a physician experienced in the diagnosis and treatment of hereditary angioedema.
Posology in adults, adolescents and children aged 2 years and above
Body weight up to 84 kg
- One intravenous injection of 50 U/kg body weight.
Body weight of 84 kg or greater
- One intravenous injection of 4200 U (2 vials).
In the majority of cases, a single dose of Ruconest is sufficient to treat an acute angioedema attack.
In case of an insufficient clinical response, an additional dose (50 U/kg body weight up to 4200 U) can be administered (see section 5.1).
- In adults and adolescents an additional dose may be administered if the patient has not responded adequately after 120 minutes.
- In children an additional dose may be administered if the patient has not responded adequately after 60 minutes.
Not more than two doses should be administered within 24 hours.
Dose calculation
Determine the patient's body weight.
Body weight up to 84 kg
- For patients up to 84 kg calculate the volume required to be administered according to the formula below:
Body weight of 84 kg or greater
- For patients of 84 kg or above the volume required to be administered is 28 ml, corresponding to 4200 U (2 vials).
Paediatric population
Ruconest may be used in paediatric patients (2 years and older) at the same dose as in adults (50 U/kg body weight).
The safety and efficacy of Ruconest in children less than 2 years old have not been established. No clinical data are available.
Elderly (≥65 years old)
Data in patients older than 65 years are limited.
There is no rationale for patients older than 65 years to respond differently to Ruconest.
Renal impairment
No dose adjustment is necessary in patients with renal impairment since conestat alfa does not undergo renal clearance.
Hepatic impairment
There is no clinical experience with Ruconest in patients with hepatic impairment. Hepatic impairment may prolong the plasma half-life of conestat alfa, but this is not thought to be a clinical concern. No recommendation on a dose adjustment can be made.
Method of administration
For intravenous use.
Ruconest must be administered by a healthcare professional until the patient (or caregiver) is competent to administer after having been properly trained and in agreement with the healthcare professional.
For instructions on reconstitution of Ruconest before administration, see section 6.6.
The required volume of the reconstituted solution should be administered as a slow intravenous injection over approximately 5 minutes.
• Known or suspected allergy to rabbits (see section 4.4)
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered products should be clearly recorded.
Conestat alfa is derived from milk of transgenic rabbits and contains traces of rabbit protein. Before initiating treatment with Ruconest, patients should be queried about prior exposure to rabbits and signs and symptoms suggestive of an allergic reaction.
Hypersensitivity reactions cannot be excluded and may have symptoms similar to angioedema attacks.
All patients must be closely monitored and carefully observed for any symptoms of hypersensitivity during and after the administration period. Patients should be informed of the early signs of hypersensitivity reactions e.g., hives, generalised urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. If these symptoms occur after administration, they should alert their physician.
In case of anaphylactic reactions or shock, emergency medical treatment should be administered.
Although cross-reactivity between cow milk and rabbit milk is considered unlikely, the possibility of such a cross-reactivity in a patient who has evidence of clinical allergy to cow milk cannot be excluded and the patient should be observed for signs and symptoms of hypersensitivity following Ruconest administration.
Thromboembolic events
Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of plasma derived C1 esterase inhibitor products in patients with known risk factors (e.g., indwelling catheters, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, immobility). Patients with known risk factors should be monitored closely.
Sodium
Each vial of Ruconest contains 19.5 mg of sodium. To be taken into consideration by patients on a controlled sodium diet.
Home-treatment and self-administration
There are limited data on the use of this medicinal product in home- or self-administration. Potential risks associated with home-treatment are related to the administration itself as well as the handling of adverse reactions, particularly hypersensitivity. The decision on the use of home-treatment for an individual patient should be made by the treating physician, who should ensure that appropriate training is provided and the use reviewed at intervals.
No interaction studies have been performed.
Scientific literature indicates an interaction of tissue-type plasminogen activator (tPA) and C1-INH containing medicinal products. Ruconest should not be administered simultaneously with tPA.
Pregnancy and breast-feeding
There is no experience with the use of Ruconest in pregnant and breast-feeding women.
In one animal study reproductive toxicity was observed (see section 5.3). Ruconest is not recommended for use during pregnancy or breast-feeding, unless the treating physician judges the benefits to outweigh the possible risks.
Fertility
There are no data on the effects of Ruconest on male or female fertility.
Based on the known pharmacology and adverse reaction profile of Ruconest, effects on the ability to drive and use machines are not expected. However headache, vertigo and dizziness have been reported following the use of Ruconest, but may also occur as a result of an attack of HAE. Patients should be advised not to drive and use machines if they experience headache, vertigo or dizziness.
Summary of the safety profile
One case of hypersensitivity was observed in clinical trials with Ruconest. The most common adverse reaction observed after administration of Ruconest is nausea.
Tabulated lists of adverse reactions
Adverse reactions reported with Ruconest in the treatment of acute HAE attacks obtained from clinical trials and post-marketing surveillance are tabulated below. In clinical trials the incidence of adverse reactions was similar for all dose groups and did not increase upon repeated administrations.
The frequency of adverse reactions listed below is defined using the following convention:
Very common (≥1/10),Common (≥1/100 to <1/10),Uncommon (≥1/1,000 to <1/100),Rare (≥1/10,000 to <1/1,000),Very rare (<1/10,000), Not known (cannot be estimated from the available data).
System Organ Class
Adverse reaction
Frequency
Nervous system disorders
Headache
Uncommon
Vertigo
Uncommon
Hypoaesthesia
Uncommon
Dizziness
Uncommon
Ear and labyrinth disorders
Auricular swelling
Uncommon
Respiratory, thoracic and mediastinal disorders
Throat irritation
Uncommon
Gastrointestinal disorders
Nausea
Common
Diarrhoea
Uncommon
Abdominal discomfort
Uncommon
Oral paraesthesia
Uncommon
Skin and subcutaneous tissue disorders
Urticaria
Uncommon
Immune system disorders
Anaphylaxis*
Uncommon
Hypersensitivity reactions*
Not known
*Further information is found in section 4.4
Paediatric population
In the clinical development program, 37 children and adolescents (aged 5 to 17 years) with HAE were treated for 124 acute angioedema attacks. Frequency, type and severity of adverse reactions in children and adolescents were similar to those in adults.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
No clinical information on overdose is available.
Ask anything about Ruconest 2100 U powder and solvent for solution for injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.